Efficacy and Safety of Losartan in Children With Ig A Nephropathy
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy
Sponsor: Ministry of Food and Drug Safety, Korea
Listed as NCT02232776, this PHASE3 trial focuses on Glomerulonephritis, IGA and remains completed. Sponsored by Ministry of Food and Drug Safety, Korea, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ministry of Food and Drug Safety, Korea
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .